Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.

In general, the percent activated T-cells was not significantly different between the groups, although there was a marked trend towards decreased activated T-cells in tumors grown in the absence of host SPARC, regardless of losartan treatment ( Figure 7A , p = 0.0507).

also in 422 other papers